ClinicalTrials.gg
CompletedNCT01385566Updated Jun 23, 2016Results posted

A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

A Phase 1 interventional study of ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous and ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
12th of 29
223 · median 160
Started
2011
with 3 others
Phase 1
3 of 29
none open now
Registered
14th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 12th largest by enrollment, is one of 4 that started in 2011, is one of 3 in phase 1, and was the 14th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

This study will compare the safety and immunogenicity of ZOSTAVAX™ (V211) administered both intradermally and subcutaneously at various doses.

Read the detailed description

This is an exploratory, randomized, partially blinded, multicenter clinical study designed to compare safety and biomarkers of varicella zoster virus immunogenicity when administering ZOSTAVAX™ (V211) at various doses both intradermally and subcutaneously in healthy male and female participants 50 years of age and older.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior history of varicella (chickenpox) or residence in a country with endemic varicella zoster virus infection for at least 30 years
  • Temperature less than 100.4 °F on day of vaccination
  • Female participants of must have a negative pregnancy test and agree to remain abstinent or use two acceptable methods for 3 months postvaccination
  • In good health

Exclusion criteria

Exclusion Criteria:

  • History of reaction to any vaccine component, including gelatin or neomycin
  • Household exposure to pregnant women who have not had chickenpox and have not been vaccinated against varicella or to /immunodeficient individuals
  • Household or workplace exposure to children 18 months and younger who have not been vaccinated against varicella
  • Prior history of herpes zoster
  • Prior receipt of any varicella or zoster vaccine
  • Received or is expected to receive immune globulin and/or blood products from 5 months prior to randomization through 42 days after vaccination
  • On immunosuppressive therapy
  • Known or suspected immune dysfunction
  • Received a or is scheduled to receive a live virus vaccine from 4 weeks prior to study vaccination through the completion of all study visits
  • Received any inactivated vaccine or is scheduled to receive any inactivated vaccine from 7 days prior to study vaccination through 7 days postvaccination, except for inactivated influenza vaccine
  • Not ambulatory
  • Pregnant or breastfeeding
  • Use of nontopical antiviral therapy with activity against herpes viruses
  • Active untreated tuberculosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
223 participants (actual)

Study arms

  • Active comparator
    Full Dose Subcutaneous

    Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous · Biological: Intradermal Placebo

  • Experimental
    1/3 Dose Subcutaneous

    Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous · Biological: Intradermal Placebo

  • Experimental
    Full Dose Intradermal

    Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal · Biological: Full Dose Intradermal Placebo

  • Experimental
    1/3 Dose Intradermal

    Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo

  • Experimental
    1/10 Dose Intradermal

    Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo

  • Experimental
    1/27 Dose Intradermal

    Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.

    Biological: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal · Biological: Intradermal Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies

    VZV antibody titers were measured by glycoprotein enzyme-linked immunosorbent assay at baseline and at 6 weeks after vaccine administration. The geometric mean fold change represents the 6-week value / the baseline value.

    Time frame: Baseline and 6 weeks following vaccine administration

  2. Number of Participants Reporting an Adverse Experience (AE)

    An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

    Time frame: Up to 42 days following vaccine administration

  3. Number of Participants Reporting a Serious Adverse Experience (SAE)

    An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention.

    Time frame: Up to 42 days following vaccine administration

  4. Number of Participants Reporting a Serious Adverse Experience

    An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention

    Time frame: Within 5 days after the blood draw at approximately 20 months following vaccine administration

  5. Number of Participants Reporting Specific Local Injection-site Adverse Experiences Prompted for on the Vaccine Report Card (VRC)

    The VRC actively prompts for local injection-site AEs of redness, swelling, and pain/tenderness and for the size of local injection-site reactions of redness and swelling that occur within 5 days of vaccination. The presence of varicella/varicella-like rash and herpes zoster/herpes zoster-like rash is also captured on the VRC. Participants receiving an injection in both limbs will be instructed to complete injection-site reaction information for each limb. All injection-site AEs were reported for the limb in which they occurred: V211 vaccine or placebo.

    Time frame: Up to 5 days following vaccine administration

  6. Number of Participants Reporting Systemic Adverse Experiences

    Systemic AEs included all reported AEs except injection-site AEs

    Time frame: Up to 42 days following vaccine administration

  7. Number of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like)

    Non-injection-site rashes were examined by a study physician. Rashes suspected to be varicella/varicella-like or herpes zoster/herpes zoster-like were sampled for verification by polymerase chain reaction.

    Time frame: Up to 42 days following vaccine administration

07

Results

Posted Feb 21, 2013

Participant flow

Participant flow — Overall Study
MilestoneFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Started523434353434
Completed513434343434
Not completed100100
Withdrew: Lost to follow-up100000
Withdrew: Withdrawal by subject000100

Outcome measures

PrimaryGeometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies

VZV antibody titers were measured by glycoprotein enzyme-linked immunosorbent assay at baseline and at 6 weeks after vaccine administration. The geometric mean fold change represents the 6-week value / the baseline value.

Time frame:
Baseline and 6 weeks following vaccine administration
Reported as:
Geometric mean · Geometric mean fold change
Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies
Geometric mean fold changeFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies1.74 (1.48 to 2.05)1.64 (1.35 to 2.00)3.24 (2.66 to 3.94)2.45 (2.02 to 2.97)2.21 (1.82 to 2.69)1.64 (1.35 to 2.00)
PrimaryNumber of Participants Reporting an Adverse Experience (AE)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

Time frame:
Up to 42 days following vaccine administration
Reported as:
Number · participants
Number of Participants Reporting an Adverse Experience (AE)
participantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Number of Participants Reporting an Adverse Experience (AE)301027232119
PrimaryNumber of Participants Reporting a Serious Adverse Experience (SAE)

An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention.

Time frame:
Up to 42 days following vaccine administration
Reported as:
Number · participants
Number of Participants Reporting a Serious Adverse Experience (SAE)
participantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Number of Participants Reporting a Serious Adverse Experience (SAE)000000
PrimaryNumber of Participants Reporting a Serious Adverse Experience

An SAE is any adverse experience that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect in offspring of a study participant, is a cancer, or is another important medical event when, based on appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention

Time frame:
Within 5 days after the blood draw at approximately 20 months following vaccine administration
Reported as:
Number · Participants
Number of Participants Reporting a Serious Adverse Experience
ParticipantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Number of Participants Reporting a Serious Adverse Experience000000
PrimaryNumber of Participants Reporting Specific Local Injection-site Adverse Experiences Prompted for on the Vaccine Report Card (VRC)

The VRC actively prompts for local injection-site AEs of redness, swelling, and pain/tenderness and for the size of local injection-site reactions of redness and swelling that occur within 5 days of vaccination. The presence of varicella/varicella-like rash and herpes zoster/herpes zoster-like rash is also captured on the VRC. Participants receiving an injection in both limbs will be instructed to complete injection-site reaction information for each limb. All injection-site AEs were reported for the limb in which they occurred: V211 vaccine or placebo.

Time frame:
Up to 5 days following vaccine administration
Reported as:
Number · Participants
Number of Participants Reporting Specific Local Injection-site Adverse Experiences Prompted for on the Vaccine Report Card (VRC)
ParticipantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose IntradermalPlacebo
Any injection-site AE277272219195
Injection-site anaesthesia0001000
Injection-site erythema165262016184
Injection-site haematoma2000000
Injection-site induration52121211101
Injection-site pain15589560
Injection-site pruritus1233110
Injection-site rash1000000
Injection-site scab0010000
Injection-site swelling134138672
PrimaryNumber of Participants Reporting Systemic Adverse Experiences

Systemic AEs included all reported AEs except injection-site AEs

Time frame:
Up to 42 days following vaccine administration
Reported as:
Number · participants
Number of Participants Reporting Systemic Adverse Experiences
participantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Number of Participants Reporting Systemic Adverse Experiences1266456
PrimaryNumber of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like)

Non-injection-site rashes were examined by a study physician. Rashes suspected to be varicella/varicella-like or herpes zoster/herpes zoster-like were sampled for verification by polymerase chain reaction.

Time frame:
Up to 42 days following vaccine administration
Reported as:
Number · participants
Number of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like)
participantsFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose Intradermal
Number of Participants Reporting a Non-injection-site Rash (Varicella, Varicella-like, Herpes Zoster, or Herpes Zoster-like)000000

Adverse events

Collected over Serious Adverse Events were collected up to 20 months following vaccine administration. Other Adverse Events were collected up to 84 days following vaccine administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Dose Subcutaneous—0/52 (0%)30/52 (57.7%)
1/3 Dose Subcutaneous—0/34 (0%)10/34 (29.4%)
Full Dose Intradermal—0/34 (0%)27/34 (79.4%)
1/3 Dose Intradermal—0/35 (0%)23/35 (65.7%)
1/10 Dose Intradermal—0/34 (0%)21/34 (61.8%)
1/27 Dose Intradermal—0/34 (0%)19/34 (55.9%)
Placebo—0/39 (0%)5/39 (12.8%)
Most frequent other events
Most frequent other events
EventFull Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose IntradermalPlacebo
Injection site erythemaGeneral disorders16/525/3426/3421/3516/3418/344/39
Injection site swellingGeneral disorders13/524/3413/348/356/347/342/39
Injection site indurationGeneral disorders5/522/3412/3412/3511/3410/341/39
Injection site painGeneral disorders15/525/348/349/355/346/340/39
Injection site pruritusGeneral disorders1/522/344/344/351/341/340/39
HeadacheNervous system disorders1/522/342/340/353/340/34—
NasopharyngitisInfections and infestations1/520/341/341/352/342/34—
CoughRespiratory, thoracic and mediastinal disorders0/520/340/341/352/340/34—
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/520/340/340/352/340/34—

Baseline characteristics

Age, Continuous
Age, Continuous(years)Full Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose IntradermalTotal
Mean59.9 ± 7.760.5 ± 7.562.1 ± 8.561.2 ± 8.761.6 ± 8.160.1 ± 7.160.8 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Full Dose Subcutaneous1/3 Dose SubcutaneousFull Dose Intradermal1/3 Dose Intradermal1/10 Dose Intradermal1/27 Dose IntradermalTotal
Female312017171624125
Male21141718181098
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 Aug;16(8):915-22. doi: 10.1016/S1473-3099(16)00133-X. Epub 2016 Apr 6. PubMed 27061887 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2011
First posted
Jun 30, 2011
Start
Sep 2011
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Feb 21, 2013
Last update
Jun 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01385566
Responsible party
Sponsor
First posted
Jun 30, 2011
Start date
Sep 2011
Primary completion
May 2013
Completion
May 2013
Results posted
Feb 21, 2013
Last update
Jun 23, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion